Canada’s COPD market size stood at around USD XX.X billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of around 4.8% during the forecast period.
In 2019, 842,600 Canadians were diagnosed with COPD, and this increase was being driven by the aging of the population. It is known that the primary cause for the development of COPD is tobacco smoke – the inhalation of heavily contaminated fine dust. In 90% of those affected by COPD, active smoking plays a role. However, it has been shown that also passive smoking can be a triggering factor as well as air pollution at the workplace caused by chemicals and dust. COPD is one of the most prevalent occupational diseases in Canada.
COPD is predominantly caused by smoking. Other factors, particularly occupational exposures, such as harmful dust and chemicals, may also contribute to developing COPD. Increase in prevalence of COPD patients, increase in aging population, technological advancement in the treatment of COPD, increase in pipeline products growth, initiatives implemented by the government and non-government associations for the rise in health awareness are the major factors that drive the market growth.